In 2023, the global rheumatoid arthritis medications market was valued at approximately USD 17.87 billion. With a steady upward trajectory, it is anticipated to grow to USD 27.38 billion by 2033. This growth reflects a compound annual growth rate (CAGR) of 4.6% throughout the forecast period.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5122
Recent Developments in the Rheumatoid Arthritis Medications Market
In July 2023, Biocon Biologics Ltd, a subsidiary of Biocon Ltd, announced the launch of HULIO (adalimumab fijp) injection in the US. This medication is a biosimilar to Humira (adalimumab) and is designed to treat rheumatoid arthritis, offering a more affordable alternative to the well-established drug.
In February 2022, Pfizer Inc. revealed that the US Food and Drug Administration (FDA) had agreed to review their application for ABRILADA (adalimumab-afib), a biosimilar to Humira. If approved, ABRILADA would offer patients a treatment option that could be interchanged with the original Humira, helping to broaden access to affordable arthritis care.
Also in February 2022, Biogen Inc. partnered with Xbrane Biopharma AB to jointly develop and manufacture Xcimzane, a drug currently in clinical trials. Xcimzane is being developed to be similar to CIMZIA (certolizumab pegol), another widely used medication for treating rheumatoid arthritis, with the aim of providing patients with another effective treatment option in the future.
Key Players in the Rheumatoid Arthritis Drug Market
- Boehringer Ingelheim GmbH: A global leader in pharmaceuticals and biologics, Boehringer Ingelheim focuses on innovative treatments for autoimmune diseases like rheumatoid arthritis, with a strong portfolio of biosimilars.
- AbbVie: Known for Humira, AbbVie has been a dominant player in the rheumatoid arthritis treatment space. The company continues to innovate with new therapies and biosimilars to address unmet patient needs.
- Novartis: With a wide range of treatments for autoimmune diseases, Novartis is a significant player in the rheumatoid arthritis market, working on both biologic drugs and small molecule therapies.
- Pfizer Inc.: Pfizer is a key contributor to the market with its offerings like Xeljanz (tofacitinib) and the biosimilar ABRILADA, continuing to expand its portfolio of rheumatoid arthritis medications.
- Bristol Myers Squibb: The company is known for its biologic therapies such as Orencia (abatacept) and its continued efforts to develop next-generation treatments for rheumatoid arthritis.
- F. Hoffmann-La Roche Ltd.: Roche offers multiple rheumatoid arthritis treatments, including Actemra (tocilizumab), and is committed to ongoing research into innovative therapies for autoimmune conditions.
- Johnson & Johnson: A major player with treatments like Remicade (infliximab), J&J is at the forefront of developing therapies that improve the quality of life for rheumatoid arthritis patients.
- Regeneron Pharmaceuticals, Inc.: Regeneron is involved in developing cutting-edge immunotherapies, including Dupixent (dupilumab), for conditions like rheumatoid arthritis and other autoimmune diseases.
- Amgen, Inc.: Known for its biologics, Amgen offers Enbrel (etanercept), a widely used treatment for rheumatoid arthritis, and continues to research and develop new therapies for autoimmune conditions.
- Merck KGaA: With a focus on immunology, Merck is advancing its presence in the rheumatoid arthritis market, exploring new therapies that offer improved outcomes for patients.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/rheumatoid-arthritis-drugs-market-sizing
Access exclusive insight now @ https://www.towardshealthcare.com/price/5122
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
